Novavax Reports Varying Success vs. COVID-19 Variants
Novavax electrified investors last night by announcing that its COVID-19 vaccine NVX-CoV2373 showed efficacy of 89.3% in the company’s first analysis of data from a Phase III trial in the U.K., where a variant strain (B.1.1.7) accounted for about half of all positive cases.
However, NVX-CoV2373 achieved only 60% efficacy in a Phase IIb trial in South Africa, where that country’s escape variant of the virus (B.1.351, also known as 20H/501Y.V2) was seen in 90% of cases, Novavax said.
“NVX-CoV2373 is the first vaccine to demonstrate not only high clinical efficacy against COVID-19 but also significant clinical efficacy against both the rapidly emerging U.K. and South Africa variants,” Stanley C. Erck, Novavax’s president and CEO, said in a statement.
Erck’s statement offered no details about the company’s timing for pursuing U.S. regulatory approvals, starting with an emergency use authorization (EUA) from the FDA. The company began a rolling submission to the U.K.’s regulatory agency, the Medicines and Healthcare products Regulatory Agency (MHRA), earlier this month.
Read the full article at: www.genengnews.com
Latest posts by BioBuzz Media (see all)
- Pioneering Past Informs Future as Budd Bioworks Unveils 300,000 sq. ft. cGMP BioManufacturing Space in Philadelphia - August 2, 2021
- Adaptive Phage Therapeutics Appoints Robert J. Hopkins, MD, MPH & TM, FACP, FIDSA, to Chief Medical Officer - July 30, 2021
- Delaware allocates additional $10M for Ready-to-Go Lab Space Grants - July 29, 2021
- Mason’s Michael Buschmann and team at start-up AexeRNA Therapeutics Inc. pursue patents for improved COVID-19 vaccines - July 29, 2021
- Emergent BioSolutions to Resume Manufacturing Covid-19 Vaccine at Bayview Facility - July 29, 2021